{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:04:19Z","timestamp":1788537859133,"version":"build-2803163510"},"reference-count":120,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/nsxc2205","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:33:48Z","timestamp":1738899228000},"page":"248-270","source":"Crossref","is-referenced-by-count":10,"title":["Mechanism analysis and targeted therapy of IDH gene mutation in glioma"],"prefix":"10.62347","volume":"15","author":[{"given":"Xingyuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.18632\/oncotarget.1408","article-title":"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft","volume":"4","author":"Borodovsky","year":"2013","unstructured":"Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA and Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013; 4: 1737-1747.","journal-title":"Oncotarget"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/neuonc\/noy016","article-title":"Temozolomide-associated hypermutation in gliomas","volume":"20","author":"Choi","year":"2018","unstructured":"Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM and Costello JF. Temozolomide-associated hypermutation in gliomas. Neuro Oncol 2018; 20: 1300-1309.","journal-title":"Neuro Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaneurol.2014.1205","article-title":"IDH mutation in glioma: new insights and promises for the future","volume":"71","author":"Turkalp","year":"2014","unstructured":"Turkalp Z, Karamchandani J and Das S. IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 2014; 71: 1319-1325.","journal-title":"JAMA Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B and Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.7314\/APJCP.2013.14.12.7261","article-title":"Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients","volume":"14","author":"Das","year":"2013","unstructured":"Das BR, Tangri R, Ahmad F, Roy A and Patole K. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. Asian Pac J Cancer Prev 2013; 14: 7261-7264.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.clineuro.2011.08.002","article-title":"Early prognostic factors related to progression and malignant transformation of low-grade gliomas","volume":"113","author":"Jung","year":"2011","unstructured":"Jung TY, Jung S, Moon JH, Kim IY, Moon KS and Jang WY. Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg 2011; 113: 752-757.","journal-title":"Clin Neurol Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/1477-7819-11-284","article-title":"Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients","volume":"11","author":"Takahashi","year":"2013","unstructured":"Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H and Kuratsu J. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol 2013; 11: 284.","journal-title":"World J Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives","volume":"18","author":"Yang","year":"2012","unstructured":"Yang H, Ye D, Guan KL and Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 2012; 18: 5562-5571.","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.12669\/pjms.39.3.7149","article-title":"Relationship between IDH1\/2 and TERT promoter mutation and the prognosis of human glioma patients","volume":"39","author":"Liu","year":"2023","unstructured":"Liu X, Liu M, Cao B, Qiao J and Zhang X. Relationship between IDH1\/2 and TERT promoter mutation and the prognosis of human glioma patients. Pak J Med Sci 2023; 39: 843-847.","journal-title":"Pak J Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jocn.2015.11.030","article-title":"An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy","volume":"31","author":"Yang","year":"2016","unstructured":"Yang Y, Mao Q, Wang X, Liu Y, Mao Y, Zhou Q and Luo J. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy. J Clin Neurosci 2016; 31: 56-62.","journal-title":"J Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood-2010-03-272146","article-title":"Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia","volume":"116","author":"Thol","year":"2010","unstructured":"Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J and Ganser A. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010; 116: 614-616.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","unstructured":"Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC and Gale RE. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118: 409-412.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-019-00684-6","article-title":"Novel IDH1-targeted glioma therapies","volume":"33","author":"Karpel-Massler","year":"2019","unstructured":"Karpel-Massler G, Nguyen TTT, Shang E and Siegelin MD. Novel IDH1-targeted glioma therapies. CNS Drugs 2019; 33: 1155-1166.","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/leu.2010.267","article-title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Chou","year":"2011","unstructured":"Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF and Tien HF. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011; 25: 246-253.","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/cncr.26580","article-title":"Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin","volume":"118","author":"Ravandi","year":"2012","unstructured":"Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J and Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 2012; 118: 2665-2673.","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1080\/10428194.2023.2237153","article-title":"IDH2 mutations in acute myeloid leukemia","volume":"64","author":"Babakhanlou","year":"2023","unstructured":"Babakhanlou R, DiNardo C and Borthakur G. IDH2 mutations in acute myeloid leukemia. Leuk Lymphoma 2023; 64: 1733-1741.","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Bernd HW, Sotlar K, Lorenzen J, Osieka R, Fabry U, Valent P and Horny HP. Acute myeloid leukaemia with t(8;21) associated with “occult” mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004; 57: 324-328.","DOI":"10.1136\/jcp.2003.012864"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis","volume":"7","author":"Zarnegar-Lumley S","year":"2023","unstructured":"Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O’Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S and Tarlock K. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv 2023; 7: 5941-5953.","journal-title":"Blood Adv"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Al Abri Y, Al Huneini M, Al Zadjali S and Al Rawahi M. IDH1 and IDH2 gene mutations in omani patients with acute myeloid leukemia: prognostic significance and clinic-pathologic features. Oman Med J 2024; 39: e592.","DOI":"10.5001\/omj.2023.126"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/biom10030358","article-title":"NAD- and NADPH-contributing enzymes as therapeutic targets in cancer: an overview","volume":"10","author":"Pramono","year":"2020","unstructured":"Pramono AA, Rather GM, Herman H, Lestari K and Bertino JR. NAD- and NADPH-contributing enzymes as therapeutic targets in cancer: an overview. Biomolecules 2020; 10: 358.","journal-title":"Biomolecules"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia","volume":"118","author":"Shen","year":"2011","unstructured":"Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, Yan H, Chen FF, Chen HM, Chen Z, Jin J and Chen SJ. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593-5603.","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/00019052-200312000-00001","article-title":"Advances in magnetic resonance imaging of brain tumours","volume":"16","author":"Rees","year":"2003","unstructured":"Rees J. Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 2003; 16: 643-650.","journal-title":"Curr Opin Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1212\/WNL.0b013e3182a95680","article-title":"Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation","volume":"81","author":"Wick","year":"2013","unstructured":"Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G and Weller M. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81: 1515-1522.","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11060-012-0977-2","article-title":"The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas","volume":"110","author":"Juratli","year":"2012","unstructured":"Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G and Krex D. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 2012; 110: 325-333.","journal-title":"J Neurooncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.prp.2018.04.002","article-title":"Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas","volume":"214","author":"Kim","year":"2018","unstructured":"Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY and Min KW. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Pathol Res Pract 2018; 214: 881-888.","journal-title":"Pathol Res Pract"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00401-010-0777-8","article-title":"Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis","volume":"120","author":"Metellus","year":"2010","unstructured":"Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O and Figarella-Branger D. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010; 120: 719-729.","journal-title":"Acta Neuropathol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","article-title":"TET enzymes, TDG and the dynamics of DNA demethylation","volume":"502","author":"Kohli","year":"2013","unstructured":"Kohli RM and Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013; 502: 472-479.","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3892\/or.15.6.1569","article-title":"Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients","volume":"15","author":"Genkai","year":"2006","unstructured":"Genkai N, Homma J, Sano M, Tanaka R and Yamanaka R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 2006; 15: 1569-1574.","journal-title":"Oncol Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11060-013-1107-5","article-title":"Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis","volume":"113","author":"Sun","year":"2013","unstructured":"Sun H, Yin L, Li S, Han S, Song G, Liu N and Yan C. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. J Neurooncol 2013; 113: 277-284.","journal-title":"J Neurooncol"},{"key":"ref29","unstructured":"The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/33681764\/."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network, Noushmehr H, Iavarone A and Verhaak RG. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164: 550-563.","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/neuonc\/noac064","article-title":"PI3K\/AKT\/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications","volume":"24","author":"Mohamed","year":"2022","unstructured":"Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM and Phillips JJ. PI3K\/AKT\/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro Oncol 2022; 24: 1471-1481.","journal-title":"Neuro Oncol"},{"key":"ref32","unstructured":"Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/36325335\/."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3171\/2014.3.JNS131505","article-title":"Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma","volume":"120","author":"Kanamori","year":"2014","unstructured":"Kanamori M, Kikuchi A, Watanabe M, Shibahara I, Saito R, Yamashita Y, Sonoda Y, Kumabe T, Kure S and Tominaga T. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma. J Neurosurg 2014; 120: 1288-1297.","journal-title":"J Neurosurg"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/jclinpath-2011-200227","article-title":"Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications","volume":"64","author":"Gupta","year":"2011","unstructured":"Gupta R, Webb-Myers R, Flanagan S and Buckland ME. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 2011; 64: 835-844.","journal-title":"J Clin Pathol"},{"key":"ref35","unstructured":"Liu X and Ling ZQ. Role of isocitrate dehydrogenase 1\/2 (IDH 1\/2) gene mutations in human tumors. Histol Histopathol 2015; 30: 1155-1160."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG and Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.","journal-title":"Nature"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL and Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.","journal-title":"Cancer Cell"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","article-title":"Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression","volume":"107","author":"Le","year":"2010","unstructured":"Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang CV. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010; 107: 2037-2042.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","unstructured":"Doherty JR and Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123: 3685-3692.","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"49165","DOI":"10.18632\/oncotarget.17106","article-title":"In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma","volume":"8","author":"Khurshed","year":"2017","unstructured":"Khurshed M, Molenaar RJ, Lenting K, Leenders WP and Van Noorden CJF. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Oncotarget 2017; 8: 49165-49177.","journal-title":"Oncotarget"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/neuonc\/not243","article-title":"Lactate dehydrogenase A silencing in IDH mutant gliomas","volume":"16","author":"Chesnelong","year":"2014","unstructured":"Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA and Cairncross JG. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol 2014; 16: 686-695.","journal-title":"Neuro Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.nicl.2016.06.018","article-title":"Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: implications for diagnosis and response monitoring","volume":"12","author":"Chaumeil","year":"2016","unstructured":"Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG and Ronen SM. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: implications for diagnosis and response monitoring. Neuroimage Clin 2016; 12: 180-189.","journal-title":"Neuroimage Clin"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/neuonc\/noz207","article-title":"Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas","volume":"22","author":"Ruiz-Rodado","year":"2020","unstructured":"Ruiz-Rodado V, Malta TM, Seki T, Lita A, Dowdy T, Celiku O, Cavazos-Saldana A, Li A, Liu Y, Han S, Zhang W, Song H, Davis D, Lee S, Trepel JB, Sabedot TS, Munasinghe J, Yang C, Herold-Mende C, Gilbert MR, Cherukuri MK, Noushmehr H and Larion M. Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. Neuro Oncol 2020; 22: 480-492.","journal-title":"Neuro Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α","volume":"324","author":"Zhao","year":"2009","unstructured":"Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL and Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 2009; 324: 261-265.","journal-title":"Science"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","unstructured":"Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H and Kaelin WG Jr. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-488.","journal-title":"Nature"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P and Gu A. IDH1\/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 2013; 8: e68782.","DOI":"10.1371\/journal.pone.0068782"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF and Wen PY. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol 2020; 38: 3398-3406.","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.31557\/APJCP.2023.24.9.3169","article-title":"Genetic polymorphism study of IDH 1\/2 and TET2 genes in acute myeloid leukemia patients","volume":"24","author":"Atef","year":"2023","unstructured":"Atef M, Shafik NF, H A Hassan N, Allam RM, El-Meligui YM and Abdelaziz H. Genetic polymorphism study of IDH 1\/2 and TET2 genes in acute myeloid leukemia patients. Asian Pac J Cancer Prev 2023; 24: 3169-3182.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref49","unstructured":"Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D’Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A and Verhaak RGW; GLASS Consortium. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 2022; 185: 2184-2199, e16."},{"key":"ref50","unstructured":"Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, Rykunov D, Colaprico A, Rothstein JH, Hong R, Stathias V, Cornwell M, Petralia F, Wu Y, Reva B, Krug K, Pugliese P, Kawaler E, Olsen LK, Liang WW, Song X, Dou Y, Wendl MC, Caravan W, Liu W, Cui Zhou D, Ji J, Tsai CF, Petyuk VA, Moon J, Ma W, Chu RK, Weitz KK, Moore RJ, Monroe ME, Zhao R, Yang X, Yoo S, Krek A, Demopoulos A, Zhu H, Wyczalkowski MA, McMichael JF, Henderson BL, Lindgren CM, Boekweg H, Lu S, Baral J, Yao L, Stratton KG, Bramer LM, Zink E, Couvillion SP, Bloodsworth KJ, Satpathy S, Sieh W, Boca SM, Schürer S, Chen F, Wiznerowicz M, Ketchum KA, Boja ES, Kinsinger CR, Robles AI, Hiltke T, Thiagarajan M, Nesvizhskii AI, Zhang B, Mani DR, Ceccarelli M, Chen XS, Cottingham SL, Li QK, Kim AH, Fenyö D, Ruggles KV, Rodriguez H, Mesri M, Payne SH, Resnick AC, Wang P, Smith RD, Iavarone A, Chheda MG, Barnholtz-Sloan JS, Rodland KD, Liu T and Ding L; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 2021; 39: 509-528, e20."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/neuonc\/nou100","article-title":"Editorial commentary on “Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas”","volume":"16","author":"Jenkins","year":"2014","unstructured":"Jenkins RB. Editorial commentary on “Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas”. Neuro Oncol 2014; 16: 891-892.","journal-title":"Neuro Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","unstructured":"Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W and Platten M. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med 2018; 24: 1192-1203.","journal-title":"Nat Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3325\/cmj.2023.64.383","article-title":"Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas","volume":"64","author":"Smrdel","year":"2023","unstructured":"Smrdel U, Škufca Smrdel AC, Podlesek A, Skoblar Vidmar M, Kos G, Markovic J, Jereb J, Knific J and Rus T. Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas. Croat Med J 2023; 64: 383-390.","journal-title":"Croat Med J"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"100790","DOI":"10.1016\/j.neo.2022.100790","article-title":"Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells","volume":"28","author":"Haddock","year":"2022","unstructured":"Haddock S, Alban TJ, Turcan Ş, Husic H, Rosiek E, Ma X, Wang Y, Bale T, Desrichard A, Makarov V, Monette S, Wu W, Gardner R, Manova K, Boire A and Chan TA. Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia 2022; 28: 100790.","journal-title":"Neoplasia"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"105976","DOI":"10.1016\/j.clineuro.2020.105976","article-title":"Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment","volume":"196","author":"Alan","year":"2020","unstructured":"Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Bozkurt S, Atasoy BM, Dane F and Yumuk PF. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment. Clin Neurol Neurosurg 2020; 196: 105976.","journal-title":"Clin Neurol Neurosurg"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation","volume":"115","author":"Chou","year":"2010","unstructured":"Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF and Tien HF. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010; 115: 2749-2754.","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/neuonc\/noy088","article-title":"IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas","volume":"20","author":"Zhang","year":"2018","unstructured":"Zhang L, He L, Lugano R, Roodakker K, Bergqvist M, Smits A and Dimberg A. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Neuro Oncol 2018; 20: 1505-1516.","journal-title":"Neuro Oncol"},{"key":"ref58","unstructured":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/23558169\/."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, De Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM and Kantarjian HM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018; 378: 2386-2398.","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB, Cloughesy TF, Burris HA, Maher EA, Janku F, Cote GM, De La Fuente MI, Clarke J, Steelman L, Le K, Zhang Y, Sonderfan A, Hummel D, Schoenfeld S, Yen K, Pandya SS and Wen PY. Phase 1 study of AG-881, an inhibitor of mutant IDH1\/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. J Clin Oncol 2018; 36 Suppl 15: 2002.","DOI":"10.1200\/JCO.2018.36.15_suppl.2002"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, De Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM and Yen K. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 2018; 9: 300-305.","journal-title":"ACS Med Chem Lett"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00401-017-1677-y","article-title":"Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo","volume":"133","author":"Pusch","year":"2017","unstructured":"Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M and Von Deimling A. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol 2017; 133: 629-644.","journal-title":"Acta Neuropathol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism","volume":"11","author":"Garten","year":"2015","unstructured":"Garten A, Schuster S, Penke M, Gorski T, De Giorgis T and Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol 2015; 11: 535-546.","journal-title":"Nat Rev Endocrinol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/cancers10020049","article-title":"Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies","volume":"10","author":"Madala","year":"2018","unstructured":"Madala HR, Punganuru SR, Arutla V, Misra S, Thomas TJ and Srivenugopal KS. Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies. Cancers (Basel) 2018; 10: 49.","journal-title":"Cancers (Basel)"},{"key":"ref65","unstructured":"Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/25035396\/."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40170-018-0177-4","article-title":"Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities","volume":"6","author":"Garrett","year":"2018","unstructured":"Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G and Kornblum HI. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab 2018; 6: 4.","journal-title":"Cancer Metab"},{"key":"ref67","unstructured":"A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/24740997\/."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"79722","DOI":"10.18632\/oncotarget.12944","article-title":"Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes","volume":"7","author":"Matre","year":"2016","unstructured":"Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, Majeti R, Schimmer AD, Li W, Wang T, Tiziani S and Konopleva M. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget 2016; 7: 79722-79735.","journal-title":"Oncotarget"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL and Cloughesy TF. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med 2023; 29: 615-622.","journal-title":"Nat Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"IK","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY and Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 2023; 389: 589-601.","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"117221","DOI":"10.1016\/j.bone.2024.117221","article-title":"Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib","volume":"188","author":"Funck-Brentano","year":"2024","unstructured":"Funck-Brentano T, Cohen-Solal M, Ducray F and Mandonnet E. Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib. Bone 2024; 188: 117221.","journal-title":"Bone"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"CD","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P and Döhner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 2021; 22: 1597-1608.","journal-title":"Lancet Oncol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s13311-022-01238-3","article-title":"Targeting IDH-mutant glioma","volume":"19","author":"Miller","year":"2022","unstructured":"Miller JJ. Targeting IDH-mutant glioma. Neurotherapeutics 2022; 19: 1724-1732.","journal-title":"Neurotherapeutics"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","unstructured":"Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M and Wick W. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 2021; 592: 463-468.","journal-title":"Nature"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haase S, Alghamri MS, Núñez FJ, Liu Y, Yu M, Taher A, Nunez FM, Li D, Edwards MB, Kleer CG, Appelman H, Sun Y, Zhao L, Moon JJ, Schwendeman A, Lowenstein PR and Castro MG. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J Clin Invest 2021; 131: e139542.","DOI":"10.1172\/JCI139542"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"114034","DOI":"10.1016\/j.ejca.2024.114034","article-title":"REVOLUMAB: a phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas","volume":"202","author":"Picca","year":"2024","unstructured":"Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F and Dehais C; POLA Network. REVOLUMAB: a phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Eur J Cancer 2024; 202: 114034.","journal-title":"Eur J Cancer"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cncr.33918","article-title":"Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system","volume":"128","author":"Gritsch","year":"2022","unstructured":"Gritsch S, Batchelor TT and Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer 2022; 128: 47-58.","journal-title":"Cancer"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","article-title":"World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review","volume":"8","author":"Berger","year":"2022","unstructured":"Berger TR, Wen PY, Lang-Orsini M and Chukwueke UN. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol 2022; 8: 1493-1501.","journal-title":"JAMA Oncol"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F, Figarella Branger D, Huang RY, Weller M, Mellinghoff IK, Cloughsey TF, Huse JT, Aldape K, Reifenberger G, Youssef G, Karschnia P, Noushmehr H, Peters KB, Ducray F, Preusser M and Wen PY. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: how should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol 2024; 26: 1805-1822.","DOI":"10.1093\/neuonc\/noae107"},{"key":"ref80","unstructured":"A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/34125374\/."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF and Wen PY. Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res 2021; 27: 4491-4499.","journal-title":"Clin Cancer Res"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","unstructured":"Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M and Blakeley J. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 2022; 40: 403-426.","journal-title":"J Clin Oncol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bpa.12801","article-title":"IDH mutant lower grade (WHO Grades II\/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations","volume":"30","author":"Yang","year":"2020","unstructured":"Yang RR, Shi ZF, Zhang ZY, Chan AK, Aibaidula A, Wang WW, Kwan JSH, Poon WS, Chen H, Li WC, Chung NY, Punchhi G, Chu WC, Chan IS, Liu XZ, Mao Y, Li KK and Ng HK. IDH mutant lower grade (WHO Grades II\/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol 2020; 30: 541-553.","journal-title":"Brain Pathol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11060-023-04250-5","article-title":"Updates on the WHO diagnosis of IDH-mutant glioma","volume":"162","author":"Reuss","year":"2023","unstructured":"Reuss DE. Updates on the WHO diagnosis of IDH-mutant glioma. J Neurooncol 2023; 162: 461-469.","journal-title":"J Neurooncol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","unstructured":"Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW and Aldape K; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.","journal-title":"Cancer Cell"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen","year":"2011","unstructured":"Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, Kelsey KT and Wiencke JK. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011; 103: 143-153.","journal-title":"J Natl Cancer Inst"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"8946","DOI":"10.1038\/s41598-019-45346-1","article-title":"Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers","volume":"9","author":"Unruh","year":"2019","unstructured":"Unruh D, Zewde M, Buss A, Drumm MR, Tran AN, Scholtens DM and Horbinski C. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. Sci Rep 2019; 9: 8946.","journal-title":"Sci Rep"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature04433","article-title":"Histone demethylation by a family of JmjC domain-containing proteins","volume":"439","author":"Tsukada","year":"2006","unstructured":"Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P and Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006; 439: 811-816.","journal-title":"Nature"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM and Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.","journal-title":"Cancer Cell"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-023-44209-8","article-title":"Covalent PARylation of DNA base excision repair proteins regulates DNA demethylation","volume":"15","author":"SD","year":"2024","unstructured":"Schwarz SD, Xu J, Gunasekera K, Schürmann D, Vågbø CB, Ferrari E, Slupphaug G, Hottiger MO, Schär P and Steinacher R. Covalent PARylation of DNA base excision repair proteins regulates DNA demethylation. Nat Commun 2024; 15: 184.","journal-title":"Nat Commun"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","unstructured":"Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK and Chan TA. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.","journal-title":"Nature"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1101\/gr.132738.111","article-title":"A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation","volume":"22","author":"Duncan","year":"2012","unstructured":"Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM and Yan H. A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 2012; 22: 2339-2355.","journal-title":"Genome Res"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","unstructured":"Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB and Chan TA. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet 2018; 50: 62-72.","journal-title":"Nat Genet"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","unstructured":"Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ and Kawamura A. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463-469.","journal-title":"EMBO Rep"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","unstructured":"Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O’Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK and Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478.","journal-title":"Nature"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"15164","DOI":"10.18632\/aging.203079","article-title":"Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma","volume":"13","author":"Maimaiti","year":"2021","unstructured":"Maimaiti A, Wang X, Pei Y, Nuermaimaiti N, Tuersunniyazi A, Abula Y, Feng Z, Jiang L, Shi X and Kasimu M. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma. Aging (Albany NY) 2021; 13: 15164.","journal-title":"Aging (Albany NY)"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"ME","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL and Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.","journal-title":"Cancer Cell"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature16490","article-title":"Insulator dysfunction and oncogene activation in IDH mutant gliomas","volume":"529","author":"WA","year":"2016","unstructured":"Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML and Bernstein BE. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 2016; 529: 110-114.","journal-title":"Nature"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.18632\/oncotarget.1412","article-title":"Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine","volume":"4","author":"Turcan","year":"2013","unstructured":"Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ and Chan TA. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget 2013; 4: 1729-1736.","journal-title":"Oncotarget"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1212\/WNL.0b013e3181c34ace","article-title":"IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide","volume":"73","author":"Dubbink","year":"2009","unstructured":"Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN and van den Bent MJ. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009; 73: 1792-1795.","journal-title":"Neurology"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","unstructured":"Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M and Von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-718.","journal-title":"Acta Neuropathol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"Houillier","year":"2010","unstructured":"Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M and Delattre JY. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-1566.","journal-title":"Neurology"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.chemrestox.7b00009","article-title":"Oncometabolites d- and l-2-hydroxyglutarate inhibit the AlkB family DNA repair enzymes under physiological conditions","volume":"30","author":"Chen","year":"2017","unstructured":"Chen F, Bian K, Tang Q, Fedeles BI, Singh V, Humulock ZT, Essigmann JM and Li D. Oncometabolites d- and l-2-hydroxyglutarate inhibit the AlkB family DNA repair enzymes under physiological conditions. Chem Res Toxicol 2017; 30: 1102-1110.","journal-title":"Chem Res Toxicol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.celrep.2015.11.029","article-title":"Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents","volume":"13","author":"Wang","year":"2015","unstructured":"Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D and Xiong Y. Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Rep 2015; 13: 2353-2361.","journal-title":"Cell Rep"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, De Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM and Bindra RS. 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med 2017; 9: eaal2463.","DOI":"10.1126\/scitranslmed.aal2463"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair","volume":"77","author":"Lu","year":"2017","unstructured":"Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon SI, MacDonald J, Ewend MG, Gilbert MR, Yang C and Wu J. Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair. Cancer Res 2017; 77: 1709-1718.","journal-title":"Cancer Res"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","unstructured":"Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS and Glazer PM. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet 2018; 50: 1086-1092.","journal-title":"Nat Genet"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1158\/0008-5472.CAN-16-2263","article-title":"The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicity","volume":"77","author":"Tateishi","year":"2017","unstructured":"Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS and Cahill DP. The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicity. Cancer Res 2017; 77: 4102-4115.","journal-title":"Cancer Res"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","volume":"122","author":"Chaturvedi","year":"2013","unstructured":"Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Görlich K, Wichmann M, Schwarzer A, Preller M, Thol F, Meyer J, Haemmerle R, Struys EA, Jansen EE, Modlich U, Li Z, Sly LM, Geffers R, Lindner R, Manstein DJ, Lehmann U, Krauter J, Ganser A and Heuser M. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122: 2877-2887.","journal-title":"Blood"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00401-013-1194-6","article-title":"Autophagy and oxidative stress in gliomas with IDH1 mutations","volume":"127","author":"Gilbert","year":"2014","unstructured":"Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N and Horbinski C. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol 2014; 127: 221-233.","journal-title":"Acta Neuropathol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41467-018-03905-6","article-title":"Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate","volume":"9","author":"Andronesi","year":"2018","unstructured":"Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP and Batchelor TT. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 2018; 9: 1474.","journal-title":"Nat Commun"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1416","article-title":"The role of iron and reactive oxygen species in cell death","volume":"10","author":"Dixon","year":"2014","unstructured":"Dixon SJ and Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10: 9-17.","journal-title":"Nat Chem Biol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/cdd.2015.38","article-title":"Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP+\/NADPH ratio","volume":"22","author":"Itsumi","year":"2015","unstructured":"Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF, Brenner D, Harris IS, Chio II, Afzal S, Cairns RA, Cescon DW, Elford AR, Ye J, Lang PA, Li WY, Wakeham A, Duncan GS, Haight J, You-Ten A, Snow B, Yamamoto K, Ohashi PS and Mak TW. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP+\/NADPH ratio. Cell Death Differ 2015; 22: 1837-1845.","journal-title":"Cell Death Differ"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/jnci\/djy230","article-title":"Targeting IDH1-mutated malignancies with NRF2 blockade","volume":"111","author":"Liu","year":"2019","unstructured":"Liu Y, Lu Y, Celiku O, Li A, Wu Q, Zhou Y and Yang C. Targeting IDH1-mutated malignancies with NRF2 blockade. J Natl Cancer Inst 2019; 111: 1033-1041.","journal-title":"J Natl Cancer Inst"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/imcb.12225","article-title":"The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1\/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas","volume":"97","author":"Ren","year":"2019","unstructured":"Ren F, Zhao Q, Huang L, Zheng Y, Li L, He Q, Zhang C, Li F, Maimela NR, Sun Z, Jia Q, Ping Y, Zhang Z, Chen X, Yue Y, Liu S, Cao L and Zhang Y. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1\/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Immunol Cell Biol 2019; 97: 457-469.","journal-title":"Immunol Cell Biol"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG and Kaelin WG Jr. Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma. Cell 2018; 175: 101-116, e25.","DOI":"10.1016\/j.cell.2018.08.038"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1535-7163.MCT-19-0103","article-title":"Blockade of glutathione metabolism in IDH1-mutated glioma","volume":"19","author":"Tang","year":"2020","unstructured":"Tang X, Fu X, Liu Y, Yu D, Cai SJ and Yang C. Blockade of glutathione metabolism in IDH1-mutated glioma. Mol Cancer Ther 2020; 19: 221-230.","journal-title":"Mol Cancer Ther"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1042\/bst0311441","article-title":"Reactive oxygen species in oncogenic transformation","volume":"31","author":"Behrend","year":"2003","unstructured":"Behrend L, Henderson G and Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003; 31: 1441-1444.","journal-title":"Biochem Soc Trans"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-cancerbio-041916-065808","article-title":"The two faces of reactive oxygen species in cancer","volume":"1","author":"Reczek","year":"2017","unstructured":"Reczek CR and Chandel NS. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol 2017; 1: 79-98.","journal-title":"Annu Rev Cancer Biol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0160561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:41Z","timestamp":1766022641000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0160561.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/nsxc2205","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}